Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 3/20 | 0.30 |
| ▸ | HTR1B | P28222 | 3/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26830285 | 0.85 | TNF (0.34) | TNFRIPK1P2RX7 | |
| SCHEMBL18999654 | 0.84 | CCR8 (0.33) | P2RX7BRD4 | |
| SCHEMBL12278113 | 0.78 | GPR55 (0.39) | P2RX7 | |
| SCHEMBL12278257 | 0.77 | AHR (0.38) | P2RX7BRD4 | |
| SCHEMBL29445672 | 0.77 | TNF (0.45) | TNFRIPK1P2RX7GPR84HTR1D | |
| SCHEMBL2542070 | 0.77 | TNF (0.45) | TNFRIPK1P2RX7GPR84HTR1D | |
| SCHEMBL26077499 | 0.77 | P2RX7 (0.32) | TNFRIPK1P2RX7 | |
| SCHEMBL21725759 | 0.76 | P2RX7 (0.34) | P2RX7BRD4 | |
| SCHEMBL19297128 | 0.76 | ACE2 (0.36) | P2RX7BRD4 | |
| SCHEMBL20156803 | 0.74 | NR3C1 (0.34) | TNFRIPK1P2RX7EIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268025-A1 | ATR INHIBITOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3053926-B1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | TNF 839/4885RIPK1 3291/4885P2RX7 202/4885 |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | TNF 4163/4885RIPK1 762/4885P2RX7 4081/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | TNF 2513/4885RIPK1 261/4885P2RX7 580/4885 |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | TNF 839/4885RIPK1 3291/4885P2RX7 202/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TNF 4132/4885RIPK1 921/4885P2RX7 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.